Signs a Business Partnership Agreement with Stryker Japan K.K. involves the domestic sales of products (CBF) for orthopedic surgery
Jun.
Signs a Business Partnership Agreement with Nissha Co., Ltd. involves the manufacturing of ReBOSSIS
2024
Oct.
Signs a Business Partnership Agreement with Surgical Spine, Inc. involves the domestic sales of ReBOSSIS
Apr.
Establishes our research laboratory at Nagoya Institute of Technology
Mar.
Closes the Okinawa laboratory
2023
Nov.
Signs a Business Partnership Agreement with Japan Medicalnext Co., Ltd.(now MC Healthcare,Inc.) for oral surgery, plastic surgery, and neurosurgery
2022
Nov.
Signs a Business Partnership Agreement with KYOCERA Corporation involves the domestic sales of products for oral and plastic surgery Launches of ReBOSSIS-M series
Oct.
Signs a Business Partnership Agreement with SHOFU INC. and TEIJIN MEDICAL TECHNOLOGIES Co., Ltd. involves the domestic sales of products for oral and plastic surgery
Feb.
Signs a Business Partnership Agreement with Teijin Nakashima Medical Co., Ltd. Corporation for domestic sales
2021
Sep.
Launches ReBOSSIS-J
Aug.
Establishes the Yokohama laboratory
Mar.
Obtains manufacturing and sales approval for ReBOSSIS-J aimed at the Japanese market
2020
Nov.
Closes the ORTHOREBIRTH USA office
May.
Launches “ORTHOREBIRTH Mask Filter” for mask
Mar.
Obtains approval for ReBOSSIS in India
Feb.
Obtains approval for ReBOSSIS in Taiwan
2019
Oct.
Signs a Sales Agency Agreement with KYOCERA Medical Technologies, Inc., a Kyocera Group company in the USA
Jun.
Initiates joint development of cell culture substrates with Dexerials Corporation
Mar.
Relocates the headquarters office to the current location
2018
Dec.
Launches stem cell extraction culture sheet for research
Aug.
Initiates joint development with Theradaptive Inc. in the USA for the practical application of Bone Morphogenetic Protein (BMP)
Jul.
Launches ReBOSSIS QDS in the USA
2017
Dec.
New ReBOSSIS obtains FDA 510(k) clearance for trauma in the USA
Oct.
Signs a Business Partnership Agreement with Harvester trading Co.Ltd. for the sales of ReBOSSIS in Taiwan. Initiates adipose-derived stem cell culture research with University of the Ryukyus
Jun.
New ReBOSSIS receives FDA 510(k) clearance for spine in the USA Signs a Business Partnership Agreement with CBC Co., Ltd. for the sales of ReBOSSIS in Europe.
2016
Sep.
Establishes the USA Office in Georgetown, Texas
Aug.
Outsources the manufacturing of ReBOSSIS to Kaigen Pharma Co., Ltd. Signs a Business Partnership Agreement with KiSCO Co., Ltd. for domestic sales
2015
Feb.
Launches ReBOSSIS in the USA Establishes the Okinawa laboratory
2014
Oct.
Obtains FDA 510(k) clearance in the USA for ReBOSSIS
